CSI Market
Sign In | Register

Verve Therapeutics Inc (VERV) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access VERV Annual Cash Flow →
Tracking cash flow results across Verve Therapeutics Inc to Mar 31 2024 helps illustrate how Mar 31 2025's cash generation has responded to changing business conditions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2025)
3 Months 		(Dec 31 2024) (Sep 30 2024) (Jun 30 2024) (Mar 31 2024)
Operating Activities
Income-31.03
Depreciation & amortization1.72
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue-5.29
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation11.17
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Amortization Of Premium On Marketable Securities-
Change In Fair Value Of Preferred Stock Tranche Liabilities-
Change In Fair Value Of Antidilution Rights-
Provision For Lease Losses-
Net Amortization Of Premium Accretion Of Discount On Marketable Securities-1.89
Change In Fair Value Of Success Payments Liabilities-0.22
Increase Decrease In Operating Lease Liability-1.35
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Other Receivables1.86
Increase (Decrease) in Accounts Payable0.73
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-7.52
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets2.12
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities1.87
Discontinued operations0.00
Net Cash flow from Operating Activities-27.85
Investing Activities
Capital Expenditures-1.22
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Payments to Acquire Marketable Securities-144.82
Real Estate Investments0.00
Maturities Of Marketable Securities97.87
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-48.17
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.01
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceed From Shareholder Loan-
Employee Stock Ownership Plan E S O P Cash Contributions To E S O P-
Issuance Of Share Under Employee Stock Purchase Plan-
Proceeds From Issuance Of Common Shares Net Of Commissions-
Proceeds From Issuance Of Common Stock Net Of Issuance Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.01
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-29.07
Total Cash Flow-76.01
4 historic quarters locked

Sign in to unlock the full Verve Therapeutics Inc cash flow history.

Sign In Create Free Account

About Verve Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000950170-25-070911

Figures are derived from filed reports and may be restated. Historical data is subject to revision.